Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Elorac, Inc. to Market a New Low-Cost Line of Sodium Sulfacetamide/Sulfur Topical Products

Posted on: 11 Dec 17

Elorac, Inc. announced today that it plans to introduce a low-cost line of generic sodium sulfacetamide/sulfur topical formulations for the treatment of acne, rosacea and seborrheic dermatitis.

“I believe that these products will be medically and cosmetically comparable or superior to current formulations of these ingredients,” stated Joel Bernstein, M.D., Executive Chairman of Elorac, and the original developer of a number of sodium sulfacetamide/sulfur products including the Novacet® and Avar® lines. “We expect to be able to offer this new line of products at pricing that will be a highly compelling value proposition to physicians, patients, pharmacists and payors.”

About Elorac, Inc.

Elorac, Inc. is a privately owned, specialty pharmaceutical company engaged in the development and commercialization of novel products for dermatology, allergy and oncology. Elorac’s development pipeline includes: naloxone lotion for treatment of pruritus accompanying cutaneous T-cell lymphoma, a product with orphan drug and fast-track designations from the U.S. Food and Drug Administration; cidoxepin, a highly potent histamine H1-receptor antagonist being developed for relief of chronic urticaria; and a once-weekly non-retinoid tablet for nodulocystic acne.

All trademarks are the property of their respective owners and are used here solely for identification purposes. Use of these trademarks does not imply endorsement.

View source version on

Business Wire

Last updated on: 11/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.